TeamDrive
RUS

Company

Team Drive was founded in 2011 as the brainchild of two of Russia’s most successful and prominent business leaders, Leonid Melamed (ex-CEO of Sistema JSFC*, Russia’s largest publically traded holding, and previously CEO of Rosno, Russia’s largest insurer and MTS, Russia’s largest telecommunications operator) and Vladimir Gurdus (ex-CEO of Medsi, Russia’s largest private healthcare provider). 

Having spent two decades successfully conceiving, building, operating and exiting  multi-billion-dollar brands and businesses in Russia and the CIS, Leonid and Vladimir came to the conclusion that not only could Russian assets and businesses be created that were highly competitive in Russia, but highly competitive at global scale, with concomitant returns to equity. In other words, that Russian assets, capital, talent, ideas, companies and brands represent a vast and largely untapped reservoir of investor and customer value potential, both in a Russian market context as well as in a global market context. Team Drive was created specifically to unlock this untapped value potential.

We offer an end-to-end asset management and value augmentation service in Russia with a focus on distressed or underperforming assets going all the way from initial control, creditor/investor alignment, goals/objectives definition, detailed brand and market differentiation strategy to business planning, operational execution and optimal exit, operating to global best practices. 


*Sistema JSFC is the largest publicly-traded diversified holding company in Russia and the CIS. Incorporated in 1993, Sistema is now one of Russia's top ten companies by revenues and is one of the largest investment companies in the world. The group owns a diverse set of public and private companies, which it holds in two distinct portfolios.

Media Center

  • 24 May 2018

    State Duma adopted a bill to simplify registration of drugs

    It will be possible to register drugs that have the same international nonproprietary names, but different trade names, and being manufactured at the same site. The corresponding government bill No. 327290-7 on amendments to the Federal Law “On Circulation of Medicines” was adopted by the State Duma in the third reading.

  • 23 May 2018

    Today’s realities in the development of local and contract manufacturing

    The representatives of pharmaceutical companies met at the forum of the Adam Smith Institute where they shared their views on the development of local and contract manufacturing. Victor Dmitriev, General Director of the Association of Russian Pharmaceutical Manufacturers, said that Russian manufacturers continue to consider the quality of their products as the most important issue.

  • 23 May 2018

    Russian Ministry included the Kirov region biotech cluster in its register

    The Ministry of Industry and Trade of Russia confirmed that the industrial biotechnology cluster of the Kirov region and its specialized organization “The Association of Industrial Biotechnology Cluster” comply with the requirements approved by the Decree of the Russian Government No. 779, dated July 31, 2016.

  • 22 May 2018

    Russian pharmaceutical market: stability in unstable environment

    According to DSM Group, in 2017, the Russian market was worth 1629 billion rubles, which 8% higher than in 2016. For the first time in three years, the market grew in dollar- and euro-denominated terms. In physical terms, the market growth is similar to the dynamics in value terms. Therefore, the factor of higher prices played virtually no role in expanding the market volume. In 2017, the main driver was the increase in the actual consumption of medicinal products, i.e., the growth in terms of sold packages.

Read more